Enliven Therapeutics Inc

ELVN is in a Stage 4 decline confirmed by a decisive support failure below the 9/20 EMAs, reinforcing a medium-term bearish bias. Price is extended and oversold, so timing is neutral—defer execution and look to sell into resistance around the broken $56.20–$57.50 zone on any bounce.

• ↑Stifel maintains Buy rating with $82 price target
• ↑Cash position of $895.2M funds R&D runway through 2030
• ↓Q2 2026 net loss of $32.5M ($0.49/share) highlights profitability strain